Organigram Holdings Inc. (NASDAQ: OGI) (TSX:OGI) has reached agreement with Phylos Bioscience Inc., to initiate a wide-ranging technical and commercial relationship in Canada. This innovation relationship is expected to further support Organigram’s cultivation efforts in Canada with patent-pending foundational technologies and genetics. In the future, subject to receipt of any required approvals and permits, Organigram intends to export THCV products to select legal international markets.
THCV (Delta 9-Tetrahydrocannabivarin)
THCV is a minor cannabinoid that has been shown to provide a distinctive user experience with an energizing and focused effect, low to no cognitive impairment or intoxication compared to THC and has been shown to have potential as an appetite suppressant. Phylos has developed, and is continuing to develop, proprietary …